Eli Lilly and Company $LLY Shares Acquired by Citizens National Bank Trust Department

Key Points

• Citizens National Bank Trust Department significantly increased its stake in Eli Lilly and Company by 2,440.5% in the second quarter, now owning 1,067 shares valued at approximately $832,000.
• CEO David A. Ricks purchased 1,632 shares of Eli Lilly at an average price of $644.77 per share, increasing his total holdings to 546,601 shares worth over $352 million.
• Recent analyst reports show a downward adjustment in price targets for Eli Lilly, with Guggenheim cutting their target from $942 to $875, while the stock maintains a consensus rating of "Moderate Buy" with an average price target of $938.94.

Citizens National Bank Trust Department boosted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2,440.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,067 shares of the company's stock after buying an additional 1,025 shares during the period. Citizens National Bank Trust Department's holdings in Eli Lilly and Company were worth $832,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in LLY. Brighton Jones LLC increased its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC increased its position in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after buying an additional 40 shares during the period. Wedge Capital Management L L P NC increased its position in Eli Lilly and Company by 13.9% during the first quarter. Wedge Capital Management L L P NC now owns 738 shares of the company's stock worth $610,000 after buying an additional 90 shares during the period. NewSquare Capital LLC increased its position in Eli Lilly and Company by 89.2% during the first quarter. NewSquare Capital LLC now owns 350 shares of the company's stock worth $289,000 after buying an additional 165 shares during the period. Finally, Covestor Ltd increased its position in Eli Lilly and Company by 24.9% during the first quarter. Covestor Ltd now owns 426 shares of the company's stock worth $352,000 after buying an additional 85 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on LLY. Guggenheim cut their price target on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft lowered their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Finally, Cantor Fitzgerald lowered their target price on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $938.94.

Insider Buying and Selling

In related news, CEO David A. Ricks purchased 1,632 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jamere Jackson purchased 200 shares of the business's stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Down 0.1%

LLY opened at $844.30 on Wednesday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00. The company has a market cap of $799.09 billion, a price-to-earnings ratio of 55.18, a PEG ratio of 1.18 and a beta of 0.47. The business's fifty day moving average is $736.97 and its two-hundred day moving average is $766.03. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the previous year, the firm posted $3.92 earnings per share. The business's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.